A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors.

Qian Zhang, Xin-En Huang, Li-Li Gao

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2009;63(8):603-7

PMID: 19019625

Abstract

OBJECTIVE

To obtain an optimal premedication protocol for paclitaxel liposome (Lipusu) in the treatment of solid tumors.

METHODS

From February 2005 to September 2007, 53 patients with advanced non-small-cell lung cancer (16 cases), breast cancer (14 cases), esophagus cancer (six cases), gastric cancer (16 cases), head and neck cancer (one case) were recruited from the Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute. Lipusu was delivered at 175 mg/m(2) (triweekly or divided into weekly) as a component of combined chemotherapy. Several premedications were attempted (detailed in the text).

RESULTS

The toxicity profile of premedications included: insomnia (five cases), dysphoria (three cases), hyperglycemia (two cases), fatigue (two cases), abdominal distension (one case), and vertigo (one case). No treatment-related death occurred.

CONCLUSIONS

Our recommendations for the premedication of Lipusu in the treatment of solid tumors are: (1) methylprednisolone 40 mg, administered intravenously 30 min before Lipusu, and granisetron 30 min before chemotherapy, (2) dexamethasone 2.25-3 mg taken orally 12 h and 2 h before Lipusu, and granisetron 30 min before chemotherapy.

Address: Department of Chemotherapy, Jiangsu Cancer Hospital and Research Institute, Bai Zi Tin 42, Nanjing 210009, Jiangsu Province, China.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.